



Hepatitis B Immune Globulin in Liver Transplantation Prophylaxis: An Update

Payam Dindoost¹, Seyed Mohammad Jazayeri², Seyed Moayed Alavian^{3*}

¹ Iranian Hepatitis Network, Tehran, IR Iran

² Hepatitis B Molecular Laboratory, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran

³ Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran

ARTICLE INFO

Article type:
Review Article

Article history:
Received: 11 Oct 2011
Revised: 26 Dec 2011
Accepted: 29 Jan 2012

Keywords:
Liver Transplantation
Hepatitis B Hyperimmune Globulin
Prevention and Control

ABSTRACT

Context: Liver transplantation is the best treatment option for end-stage liver disease following hepatitis B (HBV) infection. However, the high rate of recurrence of HBV infection following transplantation is a disadvantage of this option.

Evidence Acquisition: Over the past 2 decades, the gold standard of prophylactic treatment for the prevention of HBV re-infection following liver transplantation has been the administration of low- to high-dose hepatitis B immune globulin (HBIG) along with an antiviral agent to induce passive immunity.

Results: The effectiveness of HBIG in preventing the recurrence of HBV depends on the dosage, route of administration, and duration of HBIG treatment, and the viremic status at the time of transplantation. There is currently no consensus on a standardized recommendation for therapeutic options that include HBIG administration.

Conclusion: This review attempts to summarize the available data on the feasibility of such options. Most recent studies support the use of long-term combination therapy of HBIG and antiviral NAs (especially new agents).

Copyright © 2012 Kowsar Corp. All rights reserved.

► Implication for health policy/practice/research/medical education:

The article is suitable for hepatologist, internists, infectious specialists and liver transplantation departments.

► Please cite this paper as:

Dindoost P, Jazayeri SM, Alavian SM. Hepatitis B Immune Globulin and Liver Transplantation Prophylaxis: An UpDate. *Hepat Mon.*2012;12(3):168-76. DOI: 10.5812/hepatmon.832

1. Context

Globally, 30% of cirrhosis cases and 53% of primary liver cancer cases are attributed to hepatitis B infection (1), for which liver transplantation (LT) has been the only standard treatment option (2). However, the success of LT has been complicated by the high incidence (80%-100%) of recurrent graft infections, which typically occur between 6 and 12 months after LT in the absence of prophylaxis (3). This is accompanied by subsequent graft failure, rapid progression to cirrhosis, fulminant hepatitis, and patient death. The frequency of HBV reinfection is the low-

est in HBV-immune recipients (0%-18%) and is the highest in HBV-naïve recipients (70%-80%) (2, 4-9). Reinfection has been hypothesized to occur due to the presence of circulating virions at the time of LT, exposure to extra-hepatic reservoirs of HBV, or the persistence of the HBV covalently closed circular DNA (cccDNA) as a replicative intermediate (8, 10, 11). Furthermore, candidates under immunosuppressive therapy following LT commonly show a decrease in antibody titers (12) and an increase in viral replication (11, 13). Such active viral replication at the time of LT ($> 10^5$ copies/mL) was shown to be an important factor affecting HBV recurrence, sometimes regardless of immunoprophylaxis therapy (6, 14, 15). Moreover, hepatitis B infection in LT recipients who have received grafts from hepatitis B core antibody positive donors is a serious medical concern (16). Therefore, HBV-related liver disease was initially regarded as a contraindication to LT (17, 18). The morbidity and mortality caused by recurrent

* Corresponding author: Seyed Moayed Alavian, Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran. Tel: +98-2188945186, Fax: +98-2181262072, E-mail: alavian@thc.ir

HBV infection after LT were significant before the advent of effective immunoprophylaxis (19). However, in the last 2 decades, the indication for LT in patients with HBV-related end-stage liver disease has changed dramatically, and prophylactic strategies against HBV reinfection have changed outcomes for patients who undergo LT (20, 21). With adequate prophylaxis, less than 10% of the patients with HBV recurrence have to undergo repeated LT due to HBV-related graft failure (10, 22, 23).

2. Evidence Acquisition

The primary purpose of this review was three-fold. Our first aim was to clarify the effectiveness of different routes of administration, durations, and dosages of HBIg prophylactic options. The second aim was to compare 2 therapeutic options: HBIg monotherapy and HBIg therapy in conjunction with nucleos(t)ide analogues (NAs). Our third and final aim was to summarize the available studies on the different prophylaxis protocols used to prevent HBV recurrence in transplant recipients. A comprehensive search was performed in PubMed with the following Mesh search keywords: liver transplantation and HBIg monotherapy, liver transplantation and HBIg combination with NA, HBIg, and hepatitis B surface antigen (HBsAg) variants in liver transplantation. All published data from 1989 (the discovery of surface mutants) to August 2011 have been included in this review. Studies on the impact of HBIg monotherapy or HBIg therapy along with NAs on the HBV recurrence rate post-LT, HBIg route, dosage, and treatment, or mutations caused by the selective pressure following HBIg therapy were included in our analyses. Data were analyzed on the basis of sample size, rate of recurrence, and presence or absence of NAs in the different prophylactic protocols.

3. Results

3.1. HBIg and the Prophylactic Options

Over the past 2 decades, the gold standard of prophylactic treatment for the prevention of HBV reinfection following LT has been the inducement of passive immunity by administering low- to high-dose HBIg with or without antiviral NAs (10). However, a consensus on the dose, duration, or route of administration of HBIg for the prevention and/or suppression of HBV reinfection post-LT is lacking, and protocols tend to vary widely from 1 transplant center to another (24-27). However, with respect to the best practice for prophylactic strategies, most transplant programs in different centers around the world use the following 3 steps in general:

- 1) Intravenous administration of HBIg (4000-10,000 IU/mL) during the anhepatic phase.
- 2) Daily intramuscular or intravenous administration of 2000 to 10,000 IU HBIg for the first 3-7 days following LT.
- 3) High-dose therapy with 10,000 IU of HBIg every 4 weeks post-transplantation or low-dose therapy (400-2000 IU of HBIg) every 2 weeks post-transplantation to

maintain anti-HBs > 100 IU/L (10, 27).

3.2. Route of HBIg Administration

3.2.1. Intravenous Route

Traditionally, HBIg has been administered, pre-and postoperatively, at high doses, through the intravenous (IV) route. (Table 1) (4, 5, 15, 19, 25, 28-37). Despite the reported success of this method in preventing HBV recurrence post transplantation, high costs and patient incomppliance have limited the acceptance of this approach.

3.2.2. Intramuscular Route

The administration of low dose intramuscular (IM) HBIg has been discussed as an accepted alternative route to IV administration in several studies worldwide (Table 1) (2, 3, 14, 38-52). However, given the limited volumes that can be given per IM injection, only patients with low HBIg requirements are suited for IM HBIg administration (9, 53). A crossover study employed alternative IM and IV regimens; in that study, intraindividual variation in antibody levels following IM and those following IV administration of HBIg were observed, but the overall anti-HB antibodies concentrations and half-lives in different individuals were not significantly different (54).

3.2.3. Subcutaneous Route

Two studies on the subcutaneous (SC) administration of HBIg, either alone or in combination with lamivudine (LAM), to prevent recurrent HBV infection in patients who had chronic hepatitis B before LT showed that SC administration of HBIg can effectively maintain satisfactory levels of anti-HB antibodies (Table 1). Both studies suggested SC delivery of HBIg as an alternative when IM or IV dosing are not possible (55, 56). The benefits of SC administration of HBIg include the potential for self-administration by patients, lower dosage (500-1000 IU), few adverse drug effects, stability of anti-HB levels, and an especially low recurrence rate (21, 54-56).

3.3. HBIg Dose

3.3.1. High Dose HBIg Regimen

Numerous reports from different centers have shown that the continuous use of high-dose HBIg post-LT dramatically reduces the incidence of recurrent HBV infections. The high dose regimen was pioneered by Samuel *et al.*, who showed that HBV infection could be reduced in frequency by administration of high doses of HBIg for more than 6 months after LT (20). Later, 2 studies from the United States used aggressively high doses of IV HBIg, and subsequently, the recurrence rate reduced by more than 20% (57, 58). Thus, long-term, high-dose HBIg became the standard prophylaxis for HBV reinfection in most transplant centers in the 1990s, prior to the availability of effective antiviral therapies (11). Further studies indicated that HBV reinfection could be prevented in ma-

jority of patients by using high-dose HBIg protocols and subsequent close monitoring of anti-HB antibody titers to prevent prophylaxis failures, especially in patients with high HBV DNA pre-LT (*Table 1*) (4, 5, 15, 19, 25, 28-37, 52). Despite monitoring, patients with active replication still had a 16% rate of HBV recurrence. Subsequently, outcomes of a combination of high-dose IV HBIg and LAM were extensively investigated, and several studies reported a lower HBV recurrence rate (<10% at 1- to 2-year follow-up) with this combination treatment (*Table 1*) (19, 21, 40, 59, 60). However, the application of long-term high dose HBIg has been associated with high costs, inconvenience to patients, and the emergence of surface Ag mutations (4, 6, 10, 53, 61, 62).

3.3.2. Low Dose HBIg Regimen

Some reports have shown that the efficacy of the low-dose HBIg and LAM combination therapy is similar to that of the high-dose protocol (*Table 1*) (41, 42, 47). In several studies, administration of HBIg at low doses (300–800 IU) through the IM rather than the IV route has been shown to reduce the cost of prophylactic therapy, making the low-dose protocol as effective as the high-dose protocol (7, 8, 14, 19, 38, 39, 41-51, 59, 63) (*Table 1*). As a result of the combination with lamivudine, this approach was associated with similar recurrence rate and survival (40, 42) that could effectively prevent HBV recurrence after liver transplantation (2). Further, pre-LT reduction in viral replication makes the above combination therapy more effective (20, 40). Clearly, lower doses of HBIg (300–800 IU) and administration through the IM rather than the IV route reduce the cost of prophylactic therapy (8, 14, 19, 40, 42, 59). Currently, in several transplant centers in the United States, use of low doses of HBIg and a more limited duration of therapy have been shown to be sufficient in preventing HBV recurrence, as long as the appropriate therapy is started (64).

3.4. Indefinite Versus Short-Term Approaches

Indefinite HBIg prophylaxis may be required for patients with active replication at the time of initiation of LAM treatment (29). Lifelong prophylaxis by the administration of HBIg in combination with NAs has resulted in a significant reduction in recurrent hepatitis B (*Table 1*) (10, 17, 37, 65). Currently, this approach is being employed in many transplant centers in the United States, despite a lack of significant differences between the different HBIg regimens in terms of HBV recurrence 5 years after LT (65). Although compared to other treatments, indefinite, high dose HBIg treatment combined with NAs is thought to be very effective, the cost of this treatment is very high and as a result, in recent years, several centers have preferred to use short-term HBIg treatment in combination with indefinite nucleos(t)ide analogue therapy (*Table 1*) (6, 8, 38). Moreover, indefinite combination therapy with HBIg and a NA may not be required in all liver transplant recipients. Both discontinuation of HBIg and/or NAs after

a defined interval or continued treatment with antivirals alone (9, 35, 43, 63) have been applied by some centers with promising results; these centers have achieved rate of recurrence between 0% and 12.9% (*Table 1*).

3.5. Hepatitis B Immunoglobulin Monotherapy

Some studies showed that HBIg monotherapy appeared to be equivalent to combination therapy (HBIg plus antiviral NA) for prevention of HBV post-LT as being more effective at reducing the re-infection rate (21, 66). Protocols for monotherapy with high doses of HBIg (10,000 IU) have been used during the anhepatic phase followed by daily dosing during the first few days post-transplantation, with subsequent continuation adapted according to serum anti-HB antibody titers to be either short term (6 to 12 months) or indefinite (*Table 1*) (4, 5, 14, 15, 19, 28, 30-32, 34-38, 41, 47, 48, 52, 57, 67). Long-term HBIg monotherapy is generally well tolerated, although mild to moderate adverse events have been noted (21, 53). However, due to the risk of late reinfection, especially in patients with active pre-LT replication of HBV (and particularly those with a viral load greater than 10^5 copies/mL), HBIg monoprophyllaxis might not be a successful solution (*Table 1*) (4, 11, 15, 20, 68). Furthermore, monotherapy with HBIg has been shown to promote mutations in the surface genes, which may lead to a reduction in the efficacy of HBIg (4, 8, 10). Therefore, to overcome this problem, combination therapy of HBIg with NAs was introduced and has been accepted as being more effective at reducing the reinfection rate.

3.6. Combination Treatment of NAs With HBIg

The risk of recurrent hepatitis and death in transplant recipients has been lowered with the development of new antiviral agents, and the combined use of HBIg and these agents is associated with lower recurrence rates than HBIg or NA monotherapy. This prophylactic strategy includes potential concerted effects between HBIg and NA as well as shorter courses or lower doses of HBIg. In general, protocols for HBIg and antiviral NA combination therapy consist of pre-transplantation administration of antiviral agents (especially in HBV-DNA-positive patients) to reduce the viral load, followed by high doses of IV HBIg (10,000 IU/day) during the anhepatic phase, and a combination of long term antiviral NA and IV or IM HBIg following transplantation (21, 69). The use of combination therapy has become a common strategy to reduce post-LT HBV recurrence rates, and its efficacy has been investigated extensively (6, 39-41, 44, 46, 51, 63). Combination therapy appears to be an effective strategy for reducing HBV recurrence to 0 and 16% (*Table 1*) (6, 39-41, 44, 46, 51, 63), and for bringing about >90% long-term negativity for HBsAg (70, 71). Further, combination therapy is more cost effective because the dosage of HBIg, which is expensive, can be reduced, making NA and HBIg combination therapy far more economically attractive and potentially more widely available (17, 19, 40, 43, 44, 72-76). Some stud-

Table 1. The Different Studies With Different Strategies for Prevention of HBV Infection After Liver Transplantation

	HBIG ^a Route	HBIG Dose	HBIG Mono	HBV ^a Rec ^a , %	HBIG + LAM ^a	HBIG + New NA ^a	HBV Rec, %	Short Term HBIG	Indefinite HBIG
Alonso <i>et al.</i> 2003 (85)	IM ^a	Low	X	16.6	-	-	-	-	X
Angus <i>et al.</i> 2008 (41)	IM	Low	X	0	X	ADP ^a	0	-	X
Angus <i>et al.</i> 2000 (40)	IM	Low			X		0	-	X
Anselmo <i>et al.</i> 2002 (14)	IM	Low	X	48	X		11	-	X
Akyildiz <i>et al.</i> 2007 (39)	IM + IV ^a	Low			X	ADF	5.2	-	X
Buti <i>et al.</i> 2003 (73)	IM	Low	-	-	X	-	20	X	-
Compos-Varela <i>et al.</i> 2011 (38)	IM	Low	X	71	X	ENT ^a /TDF ^a /ETC ^a /ADF	7	-	X
Dadson <i>et al.</i> 2000 (86)	IM	Low	X	-	-	-	-	X	X
Faust <i>et al.</i> 2003 (87)	IM	Low	-	-	X	-	8.3	-	-
Ferretti <i>et al.</i> 2004 (75)	IM	Low	-	-	X	-	8.3	-	X
Filipponi <i>et al.</i> 2010 (88)	IM	Low	X	0	X	-	0	X	-
Gane <i>et al.</i> 2007 (42)	IM	Low	-	-	X		4	-	X
Han <i>et al.</i> 2003 (72)	IM	Low	-	-	X		0	-	X
Jiang <i>et al.</i> 2010 (69)	IM	Low	-	-	X	ADV/ENT ^b	5.5	-	X
Jiao <i>et al.</i> 2007 (89)	IM	Low	-	-	X	-	5.4	-	X
Jiménez-Pérez <i>et al.</i> 2010 (80)	IM	Low	-	-	X	ENT + TDF	0	-	X
Karademir <i>et al.</i> 2006 (90)	IM	Low	-	-	X	-	0	-	X ^b
Lu <i>et al.</i> 2008 (45)	IM	Low	-	-	X		9	X	-
Suehiro <i>et al.</i> 2005 (46)	IM	Low	-	-	X		0	-	X
Targhetta <i>et al.</i> 2006 (47)	IM	Low	X	16.6	X ^b	-	-	X, 1y	X
Takaki <i>et al.</i> 2007 (43)	IM	Low	-	-	X		0	-	-
Umeda <i>et al.</i> 2006 (48)	NA ^b	Low	X	23.7	-	-	-	-	X
Woo <i>et al.</i> 2008 (44)	IM	Low	-	-	X	ADP ^b	4.2	-	X
Wang <i>et al.</i> 2004 (49)	IM	Low	-	-	X	ADF	3	-	X
Wong <i>et al.</i> 2007 (63)	IM	Low	-	-	X	ADP ^b	12.9	X	-
Xi <i>et al.</i> 2009 (82)	IM	Low	-	-	X	ENT	11	-	X
Xie <i>et al.</i> 2010 (91)	IM	Low	-	-	X	ENT ^b	LAM15.8; ENT10	-	X
Yan <i>et al.</i> 2006 (2)	IM	Low	-	-	X		3.9	-	X
Yang <i>et al.</i> 2007 (92)	IM	Low	-	-	X	GAN ^a	4	-	X
Yilmaz <i>et al.</i> 2008 (51)	IM	Low	-	-	X	ADF	0	-	X
Yasunaka <i>et al.</i> 2011 (50)	NA	Low	-	-	X	ADP/ENT ^b	0 ^c	-	X

Zheng <i>et al.</i> 2006 (6)	IM	Low	-		X		16		X
Avolio <i>et al.</i> 2008 (28)	IV	High	X	30	X		9		X
Ben-Ari <i>et al.</i> 2003 (24)	IV	High	X	25	X	-	11		X
Chun <i>et al.</i> 2010 (93)	IV	High	X	13	X	-	10.2		X
Di Paolo <i>et al.</i> 2004 (74)	IV	High	-	-	X	-	0	X	-
Dickson <i>et al.</i> 2006 (29)	IV	High	-		X		3.3		X
Donataccio <i>et al.</i> 2006 (67)	IV	High	X	28.5	X ^b	ADF ^b	-	X	X
Dumortier <i>et al.</i> 2003 (30)	IV	High	X	23	X	-	0		X
Freshwater <i>et al.</i> 2008 (94)	IV	High	-	-	X	ADF	LAM: 62.5%; LAM + ADF: 0		X
Germer <i>et al.</i> 2003 (31)	IV	High	X	100	X ^b	X	0	-	-
Han <i>et al.</i> 2000 (19)	IV	High	X	25	X		0		X
Honaker <i>et al.</i> 2002 (52)	IV	High	X	21	X	-	0		X
Hwang <i>et al.</i> 2008 (32)	IV	High	X	6.4	X ^b	ADF/ENT ^b	-		X
Iacob <i>et al.</i> 2008 (33)	IV	High	-		X		4.8		X
Kwon <i>et al.</i> 2006 (34)	IV	High	X	0	X ^b		15		X
Lee <i>et al.</i> 2000 (95)	IV	High	X	0	X		0		X
Lee <i>et al.</i> 2004 (35)	IV	High	X	21.4	-	-	-		X
Marzano <i>et al.</i> 2001 (59)	IV	High	-	-	X	-	3	-	X
Marzano <i>et al.</i> 2005 (15)	IV	High	X	9	X	ADF	8		X
Manzarbeitia <i>et al.</i> 2002 (36)	IV	High	X	8.3	-	-	-	X, 6 mo	
Neff <i>et al.</i> 2004 (25)	IV	High	-	-	X	ADF/TDF ^b	12	X	
Roche <i>et al.</i> 2010 (4)	IV	High	X	17.7	X	ADF/TDF/ENT/FTC	0		X
Roque-Afonso <i>et al.</i> 2002 (5)	IV	High	X	6.2	-	-	-		X
Steinmuller <i>et al.</i> 2002 (37)	IV	High	X	16	X	FAM ^a	3.8		X
Anderson <i>et al.</i> 2007 (96)	IV	High	-	-	X	-	19.5		X
	IM	Low	-	-	X	-	5.9		X
Singham <i>et al.</i> 2010 (56)	SC ^a	Low	X	0	NO		-	X	
Yi <i>et al.</i> 2007 (97)	IV	High	X	6.3	X	-	13.8		X
Yoshida <i>et al.</i> 2007 (98)	IV	High	-	-	X	-	4	X	

^a Abbreviations: ADF, adefovir; ENT, entecavir; FAM, famciclovir; FTC, emtricitabine; GAN, ganciclovir; HBV, hepatitis B virus; IM, intramuscular; IV, intravenous; LAM, lamivudine; IT, liver transplantation; NA, nucleot(s)ide analogues; Rec, recurrence; SC, subcutaneous; TDF, tenofovir

^b In the case of recurrence

^c HBsAg negative but intrahepatic cccDNA positive

ies have used NA alone in cases of post-LT HBV recurrence (on patient's demand) after administration of HBIg at doses currently defined as high and low in the anhepatic phase and post-LT (Table 1) (25, 39, 67). However, combination protocols differ amongst transplantation centers and, to some extent, the reported results have been limited by small sample sizes and short-term follow-up. Nonetheless, the main problem with the use of antiviral substances before and/or after LT seems to be the evolution of resistant viral mutations, especially in high-risk patients (6, 31, 45, 77, 78). New treatment options such as adefovir dipivoxil (ADF) and entecavir have been shown to prevent post-LT HBV infection (25), resulting in improved survival in HBV-infected transplant recipients (24-26)

3.7. New NAs

Among the new NAs, adefovir (ADF) has been evaluated in different studies as a treatment option in transplant settings (15, 25, 31, 32, 39, 41, 49-51, 63) (Table 1). ADF therapy successfully suppressed HBV DNA replication and improved or stabilized HBV infection recurrence after LT (15, 39). LAM-resistant cases despite HBIg and lamivudine combination prophylaxis responded well to the addition of ADF to therapy or upon switching to ADF (4, 25, 32, 39, 63). Some studies have used entecavir, both with and without HBIg, with promising outcomes and without any cases of HBV recurrence during the follow-up period (4, 65, 79-82). A few studies on new NA drugs (ADF and entecavir) have also shown the effectiveness of these agents in the suppression of HBV replication in patients who developed lamivudine-resistance variants post-LT (Table 1). Although the use of these new antivirals for the prophylaxis of recurrent HBV infection is increasing without a concomitant increase in viral resistance, very few studies address the differences in the effect of the use of these new NAs as monotherapies or in combination with HBIg. Therefore, further studies are needed to test the effectiveness of these antivirals in combination therapies with HBIg and as monotherapeutic strategies (79, 83, 84).

4. Conclusions

Although a standard prophylactic regimen after LT is not available, the available systematic reviews and meta-analyses of clinical studies from multiple literature sources support the use of long-term combination therapy of HBIg and antiviral NAs (especially new agents). Regarding the combination strategy, the individualized prophylaxis protocols still are feasible, effective, but highly expensive. Most of the studies have a very small sample size that significantly limits the power of their findings. Future prospective multicenter and cohort studies with a longer period of follow up are needed to better define post-LT prophylactic strategies.

Acknowledgements

None declared.

Authors' Contribution

None declared.

Financial Disclosure

There was no financial disclosure.

Funding/Support

There was no funding for the current article.

References

1. Alliance WH. Viral Hepatitis. Global Policy. 2010; Available From: <http://www.worldhepatitisalliance.org/TheWHA.aspx>.
2. Yan ML, Yan LN, Li B, Zeng Y, Wen TF, Wang WT, et al. Intramuscular hepatitis B immune globulin combined with lamivudine in prevention of hepatitis B recurrence after liver transplantation. *Hepatobiliary Pancreat Dis Int*. 2006;**5**(3):360-3.
3. Zheng SS, Wu J, Liang TB, Wang WL, Huang DS, Xu X. Prophylaxis and treatment of hepatitis B virus reinfection following liver transplantation. *Hepatobiliary Pancreat Dis Int*. 2002;**1**(3):327-9.
4. Roche B, Roque-Afonso AM, Sebah M, Delvart V, Duclos-Vallee JC, Castaing D, et al. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins. *Liver Transpl*. 2010;**16**(7):885-94.
5. Roque-Afonso AM, Feray C, Samuel D, Simoneau D, Roche B, Emile JF, et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. *Gut*. 2002;**50**(1):95-9.
6. Zheng S, Chen Y, Liang T, Lu A, Wang W, Shen Y, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. *Liver Transpl*. 2006;**12**(2):253-8.
7. Yen RD, Bonatti H, Mendez J, Aranda-Michel J, Satyanarayana R, Dickson RC. Case report of lamivudine-resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor. *Am J Transplant*. 2006;**6**(5 Pt 1):1077-83.
8. Coffin CS, Terrault NA. Management of hepatitis B in liver transplant recipients. *J Viral Hepat*. 2007;**14**(Suppl 1):37-44.
9. Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. *Liver Transpl*. 2005;**11**(7):716-32.
10. Mehrabi A, Esmailzadeh M, Fonouni H, Hafezi M, Rahbari NN, Golriz M, et al. The role of HBIg as hepatitis B reinfection prophylaxis following liver transplantation. *Langenbecks Arch Surg*. 2011.
11. Lok ASF. Liver transplantation for chronic hepatitis B virus infection. 2011; Available From: www.uptodate.com.
12. Engler SH, Sauer PW, Golling M, Klar EA, Benz C, Stremmel W, et al. Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates. *Eur J Gastroenterol Hepatol*. 2001;**13**(4):363-7.
13. McMillan JS, Shaw T, Angus PW, Locarnini SA. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. *Hepatology*. 1995;**22**(1):36-43.
14. Anselmo DM, Ghobrial RM, Jung LC, Weaver M, Cao C, Saab S, et al. New era of liver transplantation for hepatitis B: a 17-year single-center experience. *Ann Surg*. 2002;**235**(5):611-9; discussion 9-20.
15. Marzano A, Gaia S, Ghisetti V, Carenzi S, Premoli A, Debernardi-Venon W, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. *Liver Transpl*. 2005;**11**(4):402-9.
16. Saab S, Waterman B, Chi AC, Tong MJ. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. *Liver Transpl*. 2010;**16**(3):300-7.
17. Vierling JM. Management of HBV Infection in Liver Transplantation Patients. *Int J Med Sci*. 2005;**2**(1):41-9.
18. Van Thiel DH, Schade RR, Gavaler JS, Shaw BW, Jr., Iwatsuki S, Starzl TE. Medical aspects of liver transplantation. *Hepatology*.

- 1984;**4**(1 Suppl):79S-83S.
19. Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. *Liver Transpl*. 2000;**6**(6):741-8.
20. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. *N Engl J Med*. 1993;**329**(25):1842-7.
21. Shafique U, Watson C. Current and Evolving Prophylactic Strategies Against Hepatitis B Virus Re-infection Following Liver Transplantation. *Euro Gastroenterol Hepatol Rev*. 2010;**6**(1):78-81.
22. Riediger C, Berberat PO, Sauer P, Gotthardt D, Weiss KH, Mehrabi A, et al. Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation. *Nephrol Dial Transplant*. 2007;**22** (Suppl 8):viii37-viii46.
23. Wang ZF, Liu C. Liver retransplantation: indications and outcomes. *Hepatobiliary Pancreat Dis Int*. 2004;**3**(2):175-8.
24. Ben-Ari Z, Mor E, Tur-Kaspa R. Experience with lamivudine therapy for hepatitis B virus infection before and after liver transplantation, and review of the literature. *J Intern Med*. 2003;**253**(5):544-52.
25. Neff GW, O'Brien C B, Nery J, Shire N, Montalbano M, Ruiz P, et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. *Liver Transpl*. 2004;**10**(11):1372-8.
26. Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, et al. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. *Transplantation*. 2003;**75**(8):1179-86.
27. van Nunen AB, de Man RA, Heijntik RA, Vossen AC, Schalm SW. Passive immunization of chronic hepatitis B patients on lamivudine therapy: a feasible issue? *J Viral Hepat*. 2002;**9**(3):221-8.
28. Avolio AW, Nure E, Pompili M, Barbarino R, Basso M, Caccamo L, et al. Liver transplantation for hepatitis B virus patients: long-term results of three therapeutic approaches. *Transplant Proc*. 2008;**40**(6):1961-4.
29. Dickson RC, Terrault NA, Ishitani M, Reddy KR, Sheiner P, Luketic V, et al. Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. *Liver Transpl*. 2006;**12**(1):124-33.
30. Dumortier J, Chevallier P, Scoazec JY, Berger F, Boillot O. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. *Am J Transplant*. 2003;**3**(8):999-1002.
31. Germer JJ, Charlton MR, Ishitani MB, Forehand CD, Patel R. Characterization of hepatitis B virus surface antigen and polymerase mutations in liver transplant recipients pre- and post-transplant. *Am J Transplant*. 2003;**3**(6):743-53.
32. Hwang S, Lee SG, Ahn CS, Kim KH, Moon DB, Ha TY, et al. Prevention of hepatitis B recurrence after living donor liver transplantation: primary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy. *Liver Transpl*. 2008;**14**(6):770-8.
33. Iacob S, Hrehoret D, Matei E, Dorobantu B, Gangone E, Gheorghe L, et al. Costs and efficacy of "on demand" low-dose immunoprophylaxis in HBV transplanted patients: experience in the Romanian program of liver transplantation. *J Gastrointest Liver Dis*. 2008;**17**(4):383-8.
34. Kwon CH, Suh KS, Cho JY, Yi NJ, Jang JJ, Lee KU. Change of hepatitis B virus DNA status in anti-HBc positive liver graft. *Korean J Hepatol*. 2006;**12**(2):191-200.
35. Lee KW, Lee DS, Lee HH, Kim SJ, Joh JW, Seo JM, et al. Prevention of de novo hepatitis B infection from HbcAb-positive donors in living donor liver transplantation. *Transplant Proc*. 2004;**36**(8):2311-2.
36. Manzarbeitia C, Reich DJ, Ortiz JA, Rothstein KD, Araya VR, Munoz SJ. Safe use of livers from donors with positive hepatitis B core antibody. *Liver Transpl*. 2002;**8**(6):556-61.
37. Steinmuller T, Seehofer D, Rayes N, Muller AR, Settmacher U, Jonas S, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. *Hepatology*. 2002;**35**(6):1528-35.
38. Campos-Varela I, Castells L, Buti M, Vargas V, Bilbao I, Rodriguez-Frias F, et al. Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIG and nucleos(t)ide analogues? *Ann Hepatol*. 2011;**10**(2):180-7.
39. Akyildiz M, Karasu Z, Zeytinlu M, Aydin U, Ozacar T, Kilic M. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. *J Gastroenterol Hepatol*. 2007;**22**(12):2130-4.
40. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against post-transplantation hepatitis B. *Liver Transpl*. 2000;**6**(4):429-33.
41. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. *Hepatology*. 2008;**48**(5):1460-6.
42. Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. *Gastroenterology*. 2007;**132**(3):931-7.
43. Takaki A, Yagi T, Iwasaki Y, Sadamori H, Matsukawa H, Matsuda H, et al. Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. *Transplantation*. 2007;**83**(2):231-3.
44. Woo HY, Choi JY, Jang JW, You CR, Bae SH, Yoon SK, et al. Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation. *J Med Virol*. 2008;**80**(11):1891-9.
45. Lu AW, Zheng SS, Wu MP, Shen Y, Yang RW. Reevaluation of the effect of lamivudine therapy preoperative to prevent HBV recurrence after liver transplantation. *Hepatobiliary Pancreat Dis Int*. 2008;**7**(4):357-61.
46. Suehiro T, Shimada M, Kishikawa K, Shimura T, Soejima Y, Yoshizumi T, et al. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation. *Liver Int*. 2005;**25**(6):1169-74.
47. Targhetta S, Villamil F, Inturri P, Pontisso P, Fagioli S, Cillo U, et al. Protocol liver biopsies in long-term management of patients transplanted for hepatitis B-related liver disease. *World J Gastroenterol*. 2006;**12**(11):1706-12.
48. Umeda M, Marusawa H, Ueda M, Takada Y, Egawa H, Uemoto S, et al. Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation. *Am J Transplant*. 2006;**6**(11):2680-5.
49. Wang ZX, Ding GS, Fu H, Zhang JJ, Chen XS, Guo WY, et al. Prevention of hepatitis B virus reinfection after orthotopic liver transplantation. *Hepatobiliary Pancreat Dis Int*. 2004;**3**(3):345-8.
50. Yasunaka T, Takaki A, Yagi T, Iwasaki Y, Sadamori H, Koike K, et al. Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis. *Hepatol Int*. 2011; [Epub ahead of print].
51. Yilmaz N, Shiffman ML, Todd Stravitz R, Sterling RK, Luketic VA, Sanyal AJ, et al. Prophylaxis against recurrence of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years. *Liver Int*. 2008;**28**(1):72-8.
52. Honaker MR, Shokouh-Amiri MH, Vera SR, Alloway RR, Grewal HP, Hardinger KL, et al. Evolving experience of hepatitis B virus prophylaxis in liver transplantation. *Transpl Infect Dis*. 2002;**4**(3):137-43.
53. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. *Hepatology*. 2000;**32**(6):1189-95.
54. Hooman N, Rifai K, Hadem J, Vaske B, Philipp G, Priess A, et al. Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. *Liver Transpl*. 2008;**14**(4):435-42.
55. Powell JJ, Apiratpracha W, Partovi N, Erb SR, Scudamore CH, Steinbrecher UP, et al. Subcutaneous administration of hepatitis B immune globulin in combination with lamivudine following

- orthotopic liver transplantation: effective prophylaxis against recurrence. *Clin Transplant*. 2006;**20**(4):524-5.
56. Singham J, Greanya ED, Lau K, Erb SR, Partovi N, Yoshida EM. Efficacy of maintenance subcutaneous hepatitis B immune globulin (HBIG) post-transplant for prophylaxis against hepatitis B recurrence. *Ann Hepatol*. 2010;**9**(2):166-71.
 57. McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. *Transplantation*. 1996;**61**(9):1358-64.
 58. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. *Hepatology*. 1996;**24**(6):1327-33.
 59. Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. *J Hepatol*. 2001;**34**(6):903-10.
 60. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. *Hepatology*. 1998;**28**(2):585-9.
 61. Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum Buschenfelde KH, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. *Hepatology*. 1998;**27**(1):254-63.
 62. Gow PJ, Mutimer D. Mechanisms of hepatitis B virus escape after immunoglobulin therapy. *Curr Opin Infect Dis*. 2000;**13**(6):643-6.
 63. Wong SN, Chu CJ, Wai CT, Howell T, Moore C, Fontana RJ, et al. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. *Liver Transpl*. 2007;**13**(3):374-81.
 64. Degertekin B, Han SH, Keffe EB, Schiff ER, Luketic VA, Brown RS, Jr., et al. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. *Am J Transplant*. 2010;**10**(8):1823-33.
 65. Deeney HN, Dusheiko GM. Lamivudine combined with hepatitis B immunoglobulin in for prophylaxis of hepatitis B recurrence after liver transplantation: time for a change? *Transpl Int*. 2009;**22**(4):385-6.
 66. Pan JJ, Thosani N, Machicao VI, Fallon MB. Current use of hepatitis B immune globulin for prevention of de novo hepatitis B in recipients receiving anti-HBc-positive livers. *Hepatol Int*. 2011;**5**(2):635-43.
 67. Donataccio D, Roggen F, De Reyck C, Verbaandert C, Bodeus M, Lerut J. Use of anti-HBc positive allografts in adult liver transplantation: toward a safer way to expand the donor pool. *Transpl Int*. 2006;**19**(1):38-43.
 68. Muller R, Samuel D, Fassati LR, Benhamou JP, Bismuth H, Alexander GJ. 'EUROHEP' consensus report on the management of liver transplantation for hepatitis B virus infection. European Concerted Action on Viral Hepatitis. *J Hepatol*. 1994;**21**(6):1140-3.
 69. Jiang L, Jiang LS, Cheng NS, Yan LN. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. *World J Gastroenterol*. 2009;**15**(20):2489-99.
 70. Papatheodoridis GV, Sevastianos V, Burroughs AK. Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. *Am J Transplant*. 2003;**3**(3):250-8.
 71. Samuel D. Management of hepatitis B in liver transplantation patients. *Semin Liver Dis*. 2004;**24**(Suppl 1):55-62.
 72. Han SH, Martin P, Edelstein M, Hu R, Kunder G, Holt C, et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. *Liver Transpl*. 2003;**9**(2):182-7.
 73. Buti M, Mas A, Prieto M, Casafont F, Gonzalez A, Miras M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIG) and lamivudine with long-term lamivudine plus HBIG in the prevention of hepatitis B virus recurrence after liver transplantation. *J Hepatol*. 2003;**38**(6):811-7.
 74. Di Paolo D, Tisone G, Piccolo P, Lenci I, Zazza S, Angelico M. Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. *Transplantation*. 2004;**77**(8):1203-8.
 75. Ferretti G, Merli M, Ginanni Corradini S, Callejon V, Tanzilli P, Masini A, et al. Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. *Transplant Proc*. 2004;**36**(3):535-8.
 76. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. *J Hepatol*. 2001;**34**(6):895-902.
 77. Terrault NA, Zhou S, McCarty RW, Pruett TL, Lake JR, Roberts JP, et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. *Hepatology*. 1998;**28**(2):555-61.
 78. Tillmann HL, Trautwein C, Bock T, Boker KH, Jackel E, Glowienka M, et al. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIG immunoglobulin after liver transplantation. *Hepatology*. 1999;**30**(1):244-56.
 79. Chotiayaputta W, Pelletier SJ, Fontana RJ, Lok AS. Long-term efficacy of nucleoside monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers. *Hepatol Int*. 2010;**4**(4):707-15.
 80. Jimenez-Perez M, Saez-Gomez AB, Mongil Poce L, Lozano-Rey JM, de la Cruz-Lombardo J, Rodrigo-Lopez JM. Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant. *Transplant Proc*. 2010;**42**(8):3167-8.
 81. Genzini T, Dos Santos RG, Pedrosa C, Curvelo LA, Noujaim HM, Crescentini F, et al. Liver transplantation in bearers of hepatitis B associated or not with delta hepatitis in the age of the new antiviral drugs: is hyperimmune globulin still necessary? *Transplant Proc*. 2010;**42**(2):496-7.
 82. Xi ZF, Xia Q, Zhang JJ, Chen XS, Han LZ, Wang X, et al. The role of entecavir in preventing hepatitis B recurrence after liver transplantation. *J Dig Dis*. 2009;**10**(4):321-7.
 83. Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, et al. Entecavir Monotherapy is Effective in Suppressing Hepatitis B Virus after Liver Transplantation. *Gastroenterology*. 2011;**141**(4):1212-9.
 84. Loomba R, Rowley AK, Wesley R, Smith KG, Liang TJ, Pucino F, et al. Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. *Clin Gastroenterol Hepatol*. 2008;**6**(6):696-700.
 85. Alonso I, Herreros de Tejada A, Moreno JM, Rubio E, Lucena JL, De la Revilla J, et al. Effectiveness of low-dose intramuscular anti-VHB immune globulin in the prophylaxis of viral B hepatitis reinfection after liver transplantation: preliminary report. *Transplant Proc*. 2003;**35**(5):1850-1.
 86. Dodson SF, de Vera ME, Bonham CA, Geller DA, Rakela J, Fung JJ. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. *Liver Transpl*. 2000;**6**(4):434-9.
 87. Faust D, Rabenau HF, Allwinn R, Caspary WF, Zeuzem S. Cost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation. *Clin Transplant*. 2003;**17**(3):254-8.
 88. Filippini F, Franchello A, Carrai P, Romagnoli R, De Simone P, Woodward MK, et al. Efficacy, safety, and pharmacokinetics of intramuscular hepatitis B immune globulin, Igantibe, for the prophylaxis of viral B hepatitis after liver transplantation. *Dig Liver Dis*. 2010;**42**(7):509-14.
 89. Jiao ZY, Yan LN, Li B, Zeng Y, Wen TF, Lu SC, et al. [Liver transplantation for chronic hepatitis B patients with lamivudine mono-

- therapy or lamivudine combined with individualized low-dose hepatitis B immunoglobulin treatment]. *Zhonghua Gan Zang Bing Za Zhi*. 2007;**15**(11):804-8.
90. Karademir S, Astarcioglu H, Akarsu M, Ozkardesler S, Ozzeybek D, Sayiner A, et al. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation. *Transplant Proc*. 2006;**38**(2):579-83.
 91. Xie SB, Zhu JY, Ying Z, Zeng LJ, Chao M, Lu MQ. Prevention and risk factors of the HBV recurrence after orthotopic liver transplantation: 160 cases follow-up study. *Transplantation*. 2010;**90**(7):786-90.
 92. Yang Y, Zhang Q, Cai CJ, Lu MQ, Li X, Jiang N, et al. Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant. *Chin Med J (Engl)*. 2007;**120**(16):1400-3.
 93. Chun J, Kim W, Kim BG, Lee KL, Suh KS, Yi NJ, et al. High viremia, prolonged Lamivudine therapy and recurrent hepatocellular carcinoma predict posttransplant hepatitis B recurrence. *Am J Transplant*. 2010;**10**(7):1649-59.
 94. Freshwater DA, Dudley T, Cane P, Mutimer DJ. Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study. *Transplantation*. 2008;**85**(8):1105-11.
 95. Lee SK, Park JH, Joh JW, Kim SJ, Choi IS, Choi SH, et al. Prophylaxis against hepatitis B recurrence following liver transplantation in HBs Ag(+) patients. *Transplant Proc*. 2000;**32**(7):2248-9.
 96. Anderson RD, Chinnakotla S, Guo L, Perrillo RP, Klintmalm GB, Davis GL. Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens. *Clin Transplant*. 2007;**21**(4):510-7.
 97. Yi NJ, Suh KS, Cho JY, Kwon CH, Lee KW, Joh JW, et al. Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation. *Liver Transpl*. 2007;**13**(3):451-8.
 98. Yoshida H, Kato T, Levi DM, Regev A, Madariaga JR, Nishida S, et al. Lamivudine monophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection. *Clin Transplant*. 2007;**21**(2):166-71.